SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.93-0.6%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (5334)1/4/2002 3:41:14 PM
From: Biomaven  Read Replies (2) of 52153
 
I was perhaps a little flippant when I dismissed my original "short answer is BMY" response.

As general-public biotech investors, we are normally operating under a huge handicap. We simply don't have access to all the information that would enable us to make a truly rational decision about a drug candidate (until we see the FDA briefing documents and an Advisory Committee transcript, that is). Until that point, we are operating mostly in the dark, with only a few scraps of light that the company carefully chooses to shed, plus a few conference presentations and/or publications, also entirely written by the company. (Plus of course the basic science, especially for those like Miljenko, Rick and Biotech Jim that can judge this accurately). Add to this that even the very best companies spin their results, and the not-so-good companies sometimes are outright deceptive.

So that's why I prepared to defer to BMY's judgement here. They had access to all the data and had every incentive to scrutinize it thoroughly. That doesn't mean to say they (or other big pharma) are perfect of course, but you have to accept that in all probability they were able to do a better analysis than we can with our limited information. It's easy to say in retrospect they must have missed something because of the rejection; however investment decisions cannot (unfortunately) be made in retrospect.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext